Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges

2026-04-03 01:54:06

Abstract generation in progress

Revvity Inc. reported mixed Q4 2025 results, with revenue growth stalling in its diagnostics segment, leading to an over 8% drop in its NYSE stock price. While the company’s Discovery & Analytical Solutions segment showed growth, conservative 2026 revenue guidance and ongoing integration challenges from its BioLegend acquisition are creating investor uncertainty. The article highlights the importance for DACH investors to monitor Revvity’s European healthtech exposure and acquisition progress.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.